Peptides Most Used in Tissue-Repair & Recovery Research
Repair-model literature clusters around a small set of compounds with complementary mechanisms. Specs, reported ranges and lot documentation for each compound.
By PX1 Research Team · August 4, 2026
Peptides Most Used in Tissue-Repair & Recovery Research
Repair-model literature clusters around a small set of compounds with complementary mechanisms.
| Compound | Class | Lowest reported study amount | Vial sizes |
|---|---|---|---|
| BPC-157 | synthetic pentadecapeptide derived from gastric juice protein BPC | 200–250 mcg | 5 mg / 10 mg |
| TB-500 (Thymosin Beta-4) | synthetic fragment of thymosin beta-4 | 2–2.5 mg | 10 mg |
| Wolverine Stack (BPC-157 + TB-500) | two-peptide repair blend | 500 mcg BPC + 2 mg TB | 10 mg blend vial |
| GHK-Cu | copper-binding tripeptide | 1–2 mg | 50 mg / 100 mg |
| KPV | C-terminal tripeptide of α-MSH | 200 mcg | 10 mg |
| ARA-290 (Cibinetide) | erythropoietin helix-B surface peptide | 2–4 mg | 16 mg |
Compound-by-compound notes
BPC-157
BPC-157 is a synthetic pentadecapeptide derived from gastric juice protein BPC studied in tissue-repair and gastrointestinal models. Standard preparation is 5 mg + 2 mL = 2.5 mg/mL (250 mcg = 10 units). Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Low arm | 200–250 mcg | daily |
| Mid arm | 500 mcg | daily |
| High arm | 500 mcg | twice daily |
Product page: BPC-157.
TB-500 (Thymosin Beta-4)
TB-500 (Thymosin Beta-4) is a synthetic fragment of thymosin beta-4 studied in actin-binding and repair-model research. Standard preparation is 10 mg + 2 mL = 5 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Loading arm | 2–2.5 mg | twice weekly × 4–6 weeks |
| Maintenance arm | 2 mg | weekly |
Product page: TB-500 (Thymosin Beta-4).
Wolverine Stack (BPC-157 + TB-500)
Wolverine Stack (BPC-157 + TB-500) is a two-peptide repair blend studied in connective-tissue repair research. Standard preparation is 10 mg blend + 2 mL = 5 mg/mL total. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Loading arm | 500 mcg BPC + 2 mg TB | as studied |
| Maintenance | half of loading | weekly |
Product page: Wolverine Stack (BPC-157 + TB-500).
GHK-Cu
GHK-Cu is a copper-binding tripeptide studied in extracellular-matrix, skin and hair-follicle research. Standard preparation is 50 mg + 5 mL = 10 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Topical models | 1–2 mg | daily |
| Subcutaneous arms | 1–2 mg | daily |
Product page: GHK-Cu.
KPV
KPV is a C-terminal tripeptide of α-MSH studied in inflammatory-signalling and mucosal research. Standard preparation is 10 mg + 2 mL = 5 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Low arm | 200 mcg | daily |
| Mid arm | 500 mcg | daily |
Product page: KPV.
ARA-290 (Cibinetide)
ARA-290 (Cibinetide) is a erythropoietin helix-B surface peptide studied in innate-repair-receptor research. Standard preparation is 16 mg + 4 mL = 4 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Standard arm | 2–4 mg | daily |
Product page: ARA-290 (Cibinetide).
How researchers evaluate material before running anything
Purity claims mean nothing without a lot-specific COA showing an HPLC chromatogram, LC-MS identity and endotoxin results. PX1 publishes all three at /coa.
How PX1 documents every lot
Every PX1 lot ships with HPLC purity, LC-MS identity, residual solvent, moisture (Karl Fischer), sterility and endotoxin data. Lot documentation is published at /purity-reports, /endotoxin-reports and /coa. Synthesis, purification, lyophilization and vial fill happen in U.S. facilities — see /manufacturing-process.
Research use only. PX1 Research supplies compounds for laboratory and in-vitro research. Nothing here is medical advice, a dosing recommendation, or an offer for human or veterinary use. Figures cited are reported from published laboratory literature.